A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.
Advances in the Treatment of Multiple Myeloma: Highlights from ASH 2023 and Beyond
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.
Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.
The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.
A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.
Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.
An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.
Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.
Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.
Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5